Brief: Nanexa Demonstrates Quarterly Semaglutide Dosing Feasibility
19/03/2026 09:24
March 19 (Reuters) - Nanexa AB NANEXA.ST: NANEXA DEMONSTRATES FEASIBILITY OF QUARTERLY SEMAGLUTIDE DOSING WITH PHARMASHELL® NANEXA AB - DATA INDICATE SEMAGLUTIDE CAN BE ADMINISTERED ONCE QUARTERLY WITH CONTROLLED PLASMA CONCENTRATION Source text: ID:nMFN3s6DPp Further company coverage: NANEXA.ST (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Nanexa AB
See all newsNanexa shares soar on €1.17 billion Novo Nordisk deal for injection technology
Brief: Nanexa And Novo Enter Global License, Collaboration Deal
Brief: Forge Nano And Nanexa To Develop Gmp-Compatible Ald Manufacturing Equipment
Brief: Nanexa Q2 Revenue Amounted To SEK 1.7 Million
Sweden's Nanexa Q1 revenue falls, loss widens